|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EIF2B5 |
Gene summary for EIF2B5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EIF2B5 | Gene ID | 8893 |
| Gene name | eukaryotic translation initiation factor 2B subunit epsilon | |
| Gene Alias | CACH | |
| Cytomap | 3q27.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q13144 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8893 | EIF2B5 | C51 | Human | Oral cavity | OSCC | 1.65e-11 | 6.51e-01 | 0.2674 |
| 8893 | EIF2B5 | C57 | Human | Oral cavity | OSCC | 2.38e-16 | 6.12e-01 | 0.1679 |
| 8893 | EIF2B5 | C06 | Human | Oral cavity | OSCC | 2.74e-06 | 1.25e+00 | 0.2699 |
| 8893 | EIF2B5 | C08 | Human | Oral cavity | OSCC | 5.80e-51 | 1.02e+00 | 0.1919 |
| 8893 | EIF2B5 | C09 | Human | Oral cavity | OSCC | 3.16e-04 | 1.80e-01 | 0.1431 |
| 8893 | EIF2B5 | LN22 | Human | Oral cavity | OSCC | 3.00e-06 | 8.33e-01 | 0.1733 |
| 8893 | EIF2B5 | LN38 | Human | Oral cavity | OSCC | 9.97e-09 | 1.11e+00 | 0.168 |
| 8893 | EIF2B5 | LN46 | Human | Oral cavity | OSCC | 3.48e-07 | 4.34e-01 | 0.1666 |
| 8893 | EIF2B5 | LP15 | Human | Oral cavity | LP | 1.04e-08 | 1.09e+00 | 0.2174 |
| 8893 | EIF2B5 | LP17 | Human | Oral cavity | LP | 9.29e-03 | 6.34e-01 | 0.2349 |
| 8893 | EIF2B5 | SYSMH1 | Human | Oral cavity | OSCC | 3.87e-34 | 6.93e-01 | 0.1127 |
| 8893 | EIF2B5 | SYSMH2 | Human | Oral cavity | OSCC | 8.31e-17 | 4.55e-01 | 0.2326 |
| 8893 | EIF2B5 | SYSMH3 | Human | Oral cavity | OSCC | 4.61e-24 | 5.67e-01 | 0.2442 |
| 8893 | EIF2B5 | SYSMH5 | Human | Oral cavity | OSCC | 2.25e-07 | 2.08e-01 | 0.0647 |
| 8893 | EIF2B5 | SYSMH6 | Human | Oral cavity | OSCC | 2.94e-06 | 2.92e-01 | 0.1275 |
| 8893 | EIF2B5 | P4_S8_cSCC | Human | Skin | cSCC | 1.28e-03 | 4.29e-02 | -0.3095 |
| 8893 | EIF2B5 | P5_S10_cSCC | Human | Skin | cSCC | 1.65e-03 | 1.14e-02 | -0.299 |
| 8893 | EIF2B5 | P1_cSCC | Human | Skin | cSCC | 8.86e-11 | 4.86e-01 | 0.0292 |
| 8893 | EIF2B5 | P2_cSCC | Human | Skin | cSCC | 3.85e-09 | 2.99e-01 | -0.024 |
| 8893 | EIF2B5 | P4_cSCC | Human | Skin | cSCC | 2.62e-15 | 4.08e-01 | -0.00290000000000005 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0034976111 | Esophagus | ESCC | response to endoplasmic reticulum stress | 192/8552 | 256/18723 | 7.15e-22 | 1.30e-19 | 192 |
| GO:0006413110 | Esophagus | ESCC | translational initiation | 100/8552 | 118/18723 | 1.16e-18 | 1.25e-16 | 100 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:0045727111 | Esophagus | ESCC | positive regulation of translation | 107/8552 | 136/18723 | 2.79e-15 | 1.68e-13 | 107 |
| GO:0034250111 | Esophagus | ESCC | positive regulation of cellular amide metabolic process | 123/8552 | 162/18723 | 3.32e-15 | 1.93e-13 | 123 |
| GO:000644617 | Esophagus | ESCC | regulation of translational initiation | 65/8552 | 79/18723 | 2.04e-11 | 7.07e-10 | 65 |
| GO:0009408110 | Esophagus | ESCC | response to heat | 77/8552 | 110/18723 | 2.01e-07 | 3.11e-06 | 77 |
| GO:0061458110 | Esophagus | ESCC | reproductive system development | 247/8552 | 427/18723 | 2.24e-07 | 3.42e-06 | 247 |
| GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:004860818 | Esophagus | ESCC | reproductive structure development | 245/8552 | 424/18723 | 2.82e-07 | 4.14e-06 | 245 |
| GO:0043434111 | Esophagus | ESCC | response to peptide hormone | 234/8552 | 414/18723 | 4.93e-06 | 5.21e-05 | 234 |
| GO:00425524 | Esophagus | ESCC | myelination | 85/8552 | 134/18723 | 2.51e-05 | 2.13e-04 | 85 |
| GO:00072724 | Esophagus | ESCC | ensheathment of neurons | 86/8552 | 136/18723 | 2.68e-05 | 2.24e-04 | 86 |
| GO:00083664 | Esophagus | ESCC | axon ensheathment | 86/8552 | 136/18723 | 2.68e-05 | 2.24e-04 | 86 |
| GO:00420636 | Esophagus | ESCC | gliogenesis | 172/8552 | 301/18723 | 3.75e-05 | 3.04e-04 | 172 |
| GO:001003827 | Esophagus | ESCC | response to metal ion | 208/8552 | 373/18723 | 5.02e-05 | 3.90e-04 | 208 |
| GO:000926619 | Esophagus | ESCC | response to temperature stimulus | 106/8552 | 178/18723 | 1.30e-04 | 8.84e-04 | 106 |
| GO:00100016 | Esophagus | ESCC | glial cell differentiation | 129/8552 | 225/18723 | 2.73e-04 | 1.65e-03 | 129 |
| GO:00459483 | Esophagus | ESCC | positive regulation of translational initiation | 23/8552 | 30/18723 | 5.47e-04 | 3.00e-03 | 23 |
| GO:00508528 | Esophagus | ESCC | T cell receptor signaling pathway | 73/8552 | 123/18723 | 1.54e-03 | 7.24e-03 | 73 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EIF2B5 | SNV | Missense_Mutation | c.512N>A | p.Arg171Lys | p.R171K | Q13144 | protein_coding | tolerated(0.08) | probably_damaging(0.991) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| EIF2B5 | SNV | Missense_Mutation | novel | c.2155G>A | p.Glu719Lys | p.E719K | Q13144 | protein_coding | tolerated_low_confidence(0.12) | benign(0.371) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
| EIF2B5 | SNV | Missense_Mutation | rs755584111 | c.1031G>A | p.Arg344Gln | p.R344Q | Q13144 | protein_coding | tolerated(0.11) | possibly_damaging(0.511) | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EIF2B5 | SNV | Missense_Mutation | c.706G>A | p.Asp236Asn | p.D236N | Q13144 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD | |
| EIF2B5 | insertion | Nonsense_Mutation | novel | c.748_749insTATAGTTCATAATACTCTTTGAAGTTGAAGACGCTG | p.Ser250delinsIleTerPheIleIleLeuPheGluValGluAspAlaGly | p.S250delinsI*FIILFEVEDAG | Q13144 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
| EIF2B5 | insertion | In_Frame_Ins | novel | c.1029_1030insTCCTGGTCT | p.Tyr343_Arg344insSerTrpSer | p.Y343_R344insSWS | Q13144 | protein_coding | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| EIF2B5 | insertion | In_Frame_Ins | novel | c.1810_1811insGAAAGGCCAGTGAAGGCCCTGGTGTCACCCCAGTCT | p.Pro604delinsArgLysAlaSerGluGlyProGlyValThrProValSer | p.P604delinsRKASEGPGVTPVS | Q13144 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| EIF2B5 | deletion | Frame_Shift_Del | novel | c.1179delN | p.Thr394ProfsTer30 | p.T394Pfs*30 | Q13144 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| EIF2B5 | deletion | Frame_Shift_Del | novel | c.1706delN | p.Ser570LeufsTer18 | p.S570Lfs*18 | Q13144 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| EIF2B5 | SNV | Missense_Mutation | novel | c.403C>A | p.Leu135Ile | p.L135I | Q13144 | protein_coding | tolerated(0.06) | probably_damaging(0.991) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |